Edition:
United Kingdom

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.73USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$4.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
195,539
52-wk High
$7.00
52-wk Low
$3.64

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

  INO.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.07 -- --
ROI: -53.08 1.79 14.61
ROE: -55.75 3.28 16.33

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

09 May 2018

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

09 May 2018

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

11 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.88 --
Novartis AG (NOVN.S) CHF81.64 -0.24
Pfizer Inc. (PFE.N) $44.06 --
Merck & Co., Inc. (MRK.N) $71.10 --
Sanofi SA (SASY.PA) €74.13 -0.37
GlaxoSmithKline plc (GSK.L) 1,526.60 -4.80
AstraZeneca plc (AZN.L) 5,658.00 -12.00

Earnings vs. Estimates